No Data
Austar Lifesciences Limited (HKG:6118) Shares Fly 83% But Investors Aren't Buying For Growth
AUSTAR: 2024 Interim Report
Austar Life Sciences (06118.HK): Achieved revenue of 0.701 billion yuan in the first half.
Austar Life Technology (06118.HK) announced on August 27th that for the six months ended June 30, 2024, the Group recorded revenue of approximately RMB 0.701 billion, a decrease of RMB 0.219 billion compared to the first half of 2023, mainly due to a 32.7% decrease in the Group's order volume for the entire year of 2023, resulting in a reduction in unfinished contracts at the beginning of the period. However, compared to the loss recorded in the first half of 2023, the net income after tax for the first half of 2024 has turned from a loss to a profit, and the order intake for the first half of 2024 has increased by 25% compared to the same period in 2023.
Express News | Austar Lifesciences H1 Revenue RMB 700.9 Million
AUSTAR: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024
Austar Lifesciences Prepares for Key Financial Review
Investors Give Austar Lifesciences Limited (HKG:6118) Shares A 27% HidingNo Data
No Data
